SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

The epigenetic mechanisms of melanoma drug resistance are poorly understood. Here, the authors develop a CRISPR-Cas9 screen targeting epigenetic regulators and discover that SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.

Guardado en:
Detalles Bibliográficos
Autores principales: Thomas Strub, Flavia G. Ghiraldini, Saul Carcamo, Man Li, Aleksandra Wroblewska, Rajendra Singh, Matthew S. Goldberg, Dan Hasson, Zichen Wang, Stuart J. Gallagher, Peter Hersey, Avi Ma’ayan, Georgina V. Long, Richard A. Scolyer, Brian Brown, Bin Zheng, Emily Bernstein
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/bec741aeed1b4f7292b8e63eab1bc699
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The epigenetic mechanisms of melanoma drug resistance are poorly understood. Here, the authors develop a CRISPR-Cas9 screen targeting epigenetic regulators and discover that SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.

Ejemplares similares